There are many important details to consider depending on the country, current laws, and professional opinions before declaring a person “clinically dead”, but what brings us here is the specific term “brain death”. This term carries other factors, such as its totality and irreversibility, but a biotechnology company called Bioquark Inc. wants to change that. The company has received “ethical approval” in India and the United States to begin experimental trials on twenty patients, which will include the use of stem cells, nerve stimulation, and laser therapy.
Restore. Regenerate. Repair what until now seems irreparable. The human body can recover from very traumatic situations, but it doesn’t solve everything. In many cases it needs a huge amount of help, and in others, even the skill of professionals who have trained for decades doesn’t seem to be enough. The brain is perhaps one of the greatest challenges modern medicine must face. Its relentless combination of complexity and delicacy means that any intervention demands extreme care, and in many countries, the term “brain death” is directly linked to “legal death”… but what if it were possible to reverse that condition?
The Experimental Project
The company’s name is Bioquark Inc., and its goal is to find a total of twenty brain-dead patients to begin a series of experimental trials on them. Its intention is to “trigger” and stimulate a regeneration process in the upper area of the spinal cord, which regulates the heartbeat and breathing. The scientists hope to apply a combination of therapies, such as the use of stem cells, peptide cocktails, and laser stimulation. The company highlights that it is the first time such a process has been approved, and they expect to see results between sixty and ninety days after its start.
Bioquark Inc.’s great mission is to develop a method that allows the human brain to regenerate damaged areas. Nature has some examples in the marine world, but transferring such an ability to the human body, well... let’s say the story is very different. We will be closely following this project, and if it succeeds, it is possible that a new era in regenerative medicine will open.
